Abstract Purpose: Recent studies have suggested that osteopontin is induced by hypoxia in head and neck cancer cell lines and its plasma level may serve as a surrogate marker for tumor hypoxia and treatment outcome in head and neck cancer.We investigated the response of osteopontin to in vitro hypoxia in nasopharyngeal carcinoma cell lines, and determined plasma osteopontin levels in nasopharyngeal carcinoma patients, nonnasopharyngeal carcinoma head and neck cancer patients, and healthy controls.We explored the relationship of plasma osteopontin and response to radiotherapy in nasopharyngeal carcinoma. Experimental Design: Nasopharyngeal carcinoma cell lines HK1, HONE-1, C666-1, and CNE-2 were treated with 0 to 48 hours of hypoxia or normoxia, +/-reoxygenation. Osteopontin secretion in the supernatant was measured by ELISA assay. Cellular osteopontin protein and mRNA were detected by Western blotting and reverse transcription-PCR, respectively. Plasma osteopontin levels in patients (n = 66; 44 nasopharyngeal carcinoma, 22 head and neck cancer) and controls (n = 29) were measured by ELISA. Results: Hypoxia has no effect on osteopontin protein and mRNA level in nasopharyngeal carcinoma cells. Only CNE-2 secreted osteopontin, and there was no significant induction by hypoxia. Plasma osteopontin levels in patients of metastatic nasopharyngeal carcinoma and head and neck cancer, but not in locoregional nasopharyngeal carcinoma, were significantly higher than in controls. In patients with locoregional nasopharyngeal carcinoma receiving curative radiotherapy (n = 31), a high (>median) pretreatment plasma osteopontin level was a significant predictor of poor response to radiotherapy (complete response rate, 40 % versus 88 %; P = 0.009), which remained significant in multivariate analysis. Conclusion: Our results suggested that the pretreatment plasma osteopontin level may be a useful biomarker of response to radiotherapy in nasopharyngeal carcinoma.
Tumor oxygenation status is well recognized as an important determinant of clinical outcome in radiotherapy (1) . Eppendorf electrode measurements of tumor oxygenation have defined an adverse effect of tumor hypoxia on prognosis after radiotherapy in head and neck cancer (2, 3) . A recent study of 18 F-MISO PET scan to assess tumor hypoxia has suggested the potential utility of this investigation to predict clinical benefit in patients undergoing hypoxia-targeting therapy (4) . However, the limited availability and technical complexities of these methods of hypoxia determination would likely preclude a wider clinical application. Hence, the availability of a simple, widely usable, and robust method of assessing tumor oxygenation that will correlate with clinical outcome is urgently needed.
Recently, the immunohistochemical detection of proteins involved in the hypoxic response of tumor cells has been studied as a method to estimate hypoxia in clinical tumor specimens. In particular, the transcription factor hypoxia inducible factor (HIF) 1-a and the genes up-regulated by HIF-1 such as carbonic anhydrase 9, have been studied as endogenous markers of tumor hypoxia in head and neck cancer (5, 6) and by our group in nasopharyngeal cancer (7, 8) . The level of both proteins is increased under hypoxia conditions, and both can be detected in routine paraffin sections by immunohistochemistry. These retrospective clinical studies have consistently shown that the high tumor expression of one of these hypoxia markers was associated with a poorer outcome after radiotherapy (see ref. 9 for a complete review). Recent reviews of the available clinical and experimental data regarding the prognostic effect and comparability with other methods of hypoxia detection have pointed out that these endogenous markers have the potential to indicate therapeutically relevant levels of hypoxia within tumors (9, 10) .
In addition, the search for circulating hypoxia markers has always been of clinical interest. Recently, Le et al. have shown that hypoxia exposure stimulated osteopontin secretion in head and neck cancer cell lines. Furthermore, they were able to show that a high level of plasma osteopontin correlated with tumor hypoxia (pO2 as measured by Eppendorf electrode) and was associated with poor clinical outcome in head and neck cancer patients (11) . An expanded follow-up study has further confirmed high plasma osteopontin as an independent predictor for tumor control and overall survival (12) .
Two recent studies from the DAHANCA group have provided further evidence on the role of osteopontin as a potential hypoxia biomarker in head and neck cancer. In the study by Nordsmark et al., 67 patients with advanced head and neck cancer were studied for pretreatment plasma osteopontin measured by ELISA, tumor oxygenation status using pO2 needle electrodes, and tumor osteopontin, HIF-1a, and carbonic anhydrase 9 by immunohistochemistry. Plasma osteopontin was found to correlate inversely with median tumor pO2. High plasma osteopontin, high HIF-1a, and high proportion of tumor pO2 V2.5 mm Hg related significantly with poorer locoregional control (13) . In the study by J Overgaard et al., plasma osteopontin level was evaluated in 320 patients with stored plasma samples from the 414 originally included patients of the randomized DAHANCA 5 trial (14) . In this study, the high level of plasma osteopontin was associated with poor prognosis after radiotherapy to head and neck cancer patients. This could be reversed by giving such patients the hypoxic sensitizer nimorazole together with radiotherapy. The study indicated that osteopontin is a predictor for clinical relevant hypoxia and may predict the patients who may benefit from hypoxic modification.
Although the clinical significance of plasma (or serum) osteopontin has been widely studied in various tumor types (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , only one study reported elevated plasma osteopontin level in a cohort of nonmetastatic nasopharyngeal carcinoma (31) . However, the relationship to treatment response was not studied. To define the implications of elevated plasma osteopontin levels in nasopharyngeal carcinoma patients, we sought to investigate the response of a panel of nasopharyngeal carcinoma cell lines to in vitro hypoxia, with or without reoxygenation, regarding the accumulation and secretion of this protein in nasopharyngeal carcinoma cells. We determined plasma osteopontin in a patient cohort that included newly diagnosed nasopharyngeal carcinoma, as well as recurrent and metastatic nasopharyngeal carcinoma. We also included cohorts of nonnasopharyngeal carcinoma head and neck cancer patients and healthy control subjects as disease and normal control, respectively. We further explored the relationship of plasma osteopontin with clinical response to radiotherapy in nasopharyngeal carcinoma.
Materials and Methods
Culture of tumor cell lines and hypoxia/reoxygenation treatment. Four nasopharygneal carcinoma cell lines (CNE-2, C666-1, HONE-1, and HK1) were used as previously described (8, 32) . The CNE-2 (33) and HONE-1 cell lines (34) were established from poorly differentiated nasopharyngeal carcinomas. The C666-1 cell line was established from a undifferentiated nasopharyngeal carcinoma and consistently carried EBV in long-term cultures (35) . The HK1 cell line was established from a well-differentiated squamous nasopharyngeal carcinoma (36) . CNE-2 and HONE-1 cells were cultured in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and antibiotics (100 units/mL penicillin and 10 Ag/mL streptomycin), whereas HK1 and C666-1 cells were cultured in RPMI 1640 supplemented with 10% FBS and antibiotics. Cell cultures were incubated at 37jC in a humid atmosphere of 5% CO 2 and 95% air (normoxia). Hypoxia was created by culturing cells in a hypoxia chamber (Galaxy R CO 2 incubator, RS Biotech Laboratory Equipment Ltd.) containing 0.1% O 2 , 5% CO 2 , and 94.9% N 2 . Reoxygenation of cells was achieved by exposure to normoxia condition after hypoxia. All culture medium and reagents were purchased from Life Technologies.
ELISA for osteopontin. For nasopharyngeal carcinoma cells, cells were seeded onto 6-well plates. Subconfluent cultures were incubated in RMPI-1% FBS under normoxia or hypoxic condition for various time intervals (4-48 h). At the end of incubation, culture medium was collected and spun at 3,000 rpm for 3 min to remove cell debris. Aliquots of the supernatant were stored at -80jC until processing. Cells were then washed with cold PBS and then lysed in lysis buffer. The amount of total protein in each well was quantified. For plasma samples, blood was drawn from healthy control subjects or patients into EDTA tubes and then spun at 3,000 rpm for 10 min. Supernatant (plasma) was collected and stored at -80jC until used. Plasma was diluted 10-fold before assayed. Osteopontin concentrations in cell culture supernatant or plasma were quantified by TiterZyme EIA human Osteopontin Enzyme Immunometric Assay Kit (Assay Designs, Inc.) according to the manufacturer's instruction. The intra-assay and interassay precision (expressed as percent coefficient of variation) ranged from 3.1% to 8.6% and from 6.3% to 10.3% (from low to high osteopontin concentration), respectively. Osteopontin secretions by nasopharyngeal carcinoma cells were normalized by total protein amount in each well and expressed in ng/Ag cellular protein.
Osteopontin levels in plasma were expressed in ng/mL.
Western immunoblotting of osteopontin in tumor cell lines. After treatment, nasopharyngeal carcinoma cells were scraped off from
Translational Relevance
This study presented interesting and clinically relevant data on the potential of the tumor-associated protein osteopontin to predict hypoxia-related resistance to radiotherapy in nasopharyngeal carcinoma. Although some data have been published on the application of plasma osteopontin to select patients with poorly oxygenated head and neck squamous cell carcinoma for hypoxia-specific treatment approaches, no corresponding knowledge exists thus far for nasopharyngeal carcinoma, a tumor entity for which radiotherapy is also a standard treatment and in which tumor oxygenation also plays an important role for response. Furthermore, there is some debate about the mechanism by which osteopontin is actually secreted into the plasma in patients with hypoxic tumors. In a translational approach, this study presented in vitro and clinical data to address these two points. The result showed convincingly in a panel of nasopharyngeal carcinoma cell lines that prolonged hypoxia with or without reoxygenation did not lead to increased cellular osteopontin mRNA or protein or increased osteopontin secretion. This finding challenged the view that osteopontin secretion is directly caused by low oxygen tension. The clinical data showed for the first time that plasma osteopontin predicted complete response to radiotherapy in nasopharyngeal carcinoma.
culture flasks and lysed. Cellular proteins were separated by SDS-PAGE. The separated proteins were electrophoretically transferred to nitrocellulose membrane. After blocking with 5% nonfat milk powder in TBS Tween 20, the membrane was incubated with primary antibody overnight at 4jC. After washing, the membrane was incubated with horseradish peroxide conjugated secondary antibodies (DAKO) for 1 h at room temperature. After washing, the enhanced chemiluminescence detection system (ECL, Amersham Biosciences) was used to visualize the protein bands. The primary antibodies used were rabbit antihuman osteopontin antibody (Assay Designs, Inc.) and mouse antihuman HIF-1a antibody (Transduction Laboratories). Actin was used as an internal control to verify equal protein loading in each nasopharyngeal carcinoma cell line during the experiment.
RNA purification and reverse transcription-PCR. After treatment, nasopharyngeal carcinoma cells were lysed by TRIzol Reagent (Invitrogen), and RNA was extracted according to the manufacturer's instruction. Reverse transcription was done by using random hexamers and MuLV reverse transcriptase (GeneAmp RNA PCR kit, Applied Biosystems), as reported previously (8) . The reverse transcription reaction was started with 10 min incubation at room temperature, 1 h at 42jC, and 5 min at 99jC, and followed by 5 min at 4jC. PCR was done using AmpliTaq Gold (Applied Biosystems). The PCR program started with an initial denaturation at 95jC for 10 min, followed by 30 cycles (94jC for 30 s, 60jC for 30 s, and 72jC for 30 s) of amplification, with a final extension at 72jC for 10 min. The reverse transcription-PCR product was electrophoresed on a 2% agarose gel containing ethidium bromide.
Patients and samples. Plasma samples were collected from consecutively consenting patients of newly diagnosed and untreated nasopharyngeal or head and neck cancer attending oncology clinics at the Department of Clinical Oncology of Prince of Wales Hospital. Written informed consent for blood collection for research purpose was obtained from all patients before blood taking. The control plasma samples were collected from volunteer staff members in good health without evidence of cancer. Additional plasma samples were collected as part of a phase 1 clinical trial of chemotherapy (cisplatin and fluorouracil combined with antiviral agent ganciclovir) in patients with recurrent or metastatic nasopharyngeal cancer. The studies on human subjects were approved by the institutional ethics committee.
Statistical analysis. Descriptive statistics (mean, SE, SD, median, and range) were used to summarize the distribution of plasma osteopontin levels. One-sample Kolmogorov-Smirnov test was used to test for normal distribution of plasma osteopontin level within each group, and the result suggested a normal distribution. Correlations between plasma osteopontin level and clinical characteristics were analyzed by Pearson's (for continuous variables) or Spearman's (for categorical variables) correlation coefficient. Student's t test was used to compare the mean plasma osteopontin of the patient group against that of healthy controls. The Mann-Whitney U test was used to compare the difference of the plasma osteopontin of the patient group with that of healthy controls. Response to radiotherapy according to plasma osteopontin level was compared by Fisher's exact test (as dichotomized variable divided by the median) and logistic regression (as a continuous variable). Univariate and multivariate logistic regression models were used to test for confounding covariates. All statistical analyses were done with SPSS for Windows release 11.5 (SPSS, Inc.). Statistical significance was set at P < 0.05 (except where a Bonferroni correction was made to adjust for multiple testing in subgroup analysis, and the significance was set at P < 0.05/n; n = number of subgroups). All reported P values were two-sided.
Results
Effect of hypoxia on osteopontin secretion and expression in nasopharyngeal carcinoma cells. Four nasopharyngeal carcinoma cell lines were incubated in hypoxia condition for various time periods (4-48 hours). Osteopontin secreted by nasopharyngeal carcinoma cells were quantified by ELISA. The results showed that only CNE-2 secreted osteopontin into culture medium (Fig. 1A) , whereas the osteopontin secretion by the other three nasopharyngeal carcinoma cell lines was undetectable under all conditions (data not shown). Hypoxia treatment did not significantly increase the osteopontin secretion by CNE-2 cells (Fig. 1A) . Cellular HIF-1a and osteopontin proteins in nasopharyngeal carcinoma cells were detected by Western blotting. Hypoxia treatment (4-48 hours) significantly increased the cellular HIF-1a protein levels in nasopharyngeal carcinoma cell lines with peaks at 4 hours of hypoxia for HONE-1, C666-1, and HK1 cells, and 16 hours of hypoxia for CNE-2 cells. HIF-1a protein levels were then declined progressively with longer incubation time. However, hypoxia did not change the cellular osteopontin protein levels in nasopharyngeal carcinoma cells (Fig. 1B) . The molecular weight of the HIF-1a protein detected was between 100 and 150 kDa, and that of osteopontin was between 50 and 75 kDa. The osteopontin mRNA levels in hypoxic nasopharyngeal carcinoma cells were determined by reverse transcription-PCR. The primers for osteopontin can detect bands for osteopontin transcript variant 1 (product size 242 bp) and variant 2 (200 bp) in nasopharyngeal carcinoma cell lines. The data suggested that 16 hours of hypoxia did not significantly change the osteopontin mRNA levels (Fig. 1C) .
Effect of hypoxia/reoxygenation on osteopontin levels in nasopharyngeal carcinoma cells. Because hypoxia followed by reoxygenation may occur in some regions of hypoxic tumors (perfusion-limited hypoxia), and previous reports suggested that reoxygenation rather than hypoxia may cause increased osteopontin production in certain cell types, we also studied the effect of hypoxia (16 hours) followed by reoxygenation (2-48 hours) on cellular osteopontin protein levels in nasopharyngeal carcinoma cells. Our results showed that reoxygenation following hypoxia did not change the cellular osteopontin protein levels in nasopharyngeal carcinoma cells (Fig. 1D) .
Plasma osteopontin in healthy controls and patients with nasopharyngeal and head and neck cancer. Plasma osteopontin was measured in 29 healthy control subjects, 44 nasopharyngeal cancer patients, and 22 head and neck cancer patients ( Table 1) . The mean and median plasma osteopontin of healthy controls were 523 ng/mL and 513 ng/mL, respectively. The mean and median plasma osteopontin of head and neck cancer patients were 728 and 695 ng/mL, respectively, which were significantly higher (even after Bonferroni correction) than that of healthy controls (P < 0.001 for the comparison of means by Student's t test, and P = 0.002 for the comparison of difference by Mann-Whitney U test; Table 2 ). The mean and median plasma osteopontin of all 44 nasopharyngeal carcinoma patients were 705 ng/mL and 582 ng/mL, respectively, which were, however, not significantly different from that of healthy controls (P = 0.062 by Student's t test, and P = 0.073 by Mann-Whitney U test).
Among the nasopharyngeal carcinoma or head and neck cancer patients, either tested as a combined group (n = 66) or as separate groups, there was no significant correlation between plasma osteopontin level and the following clinical parameters: gender, age, body weight, T stage, N stage, and International Union Against Cancer stages (data not shown). However, plasma osteopontin level was significantly correlated with the presence of distant metastases (Spearman's correlation coefficient, 0.28; P = 0.024). Therefore, we divided the 44 nasopharyngeal carcinoma patients into three clinical subgroups: (a) locoregional nasopharyngeal carcinoma, which represented the newly diagnosed, previously untreated, nonmetastatic nasopharyngeal carcinoma; (b) local recurrent nasopharyngeal carcinoma, comprising local recurrent nasopharyngeal carcinoma after previous radiotherapy, but without distant metastases; and (c) nasopharyngeal carcinoma with distant metastases. All patients in group (a) were treated with curative radiotherapy with or without chemotherapy. Patients in group (b) or (c) were treated with palliative chemotherapy. Table 1 summarizes the clinical characteristics of study patients.
The box and whisker plots in Fig. 2 show the distribution of plasma osteopontin levels in these three distinct clinical groups of nasopharyngeal carcinoma. It was shown that the plasma osteopontin level in locoregional nasopharyngeal carcinoma, either newly diagnosed nasopharyngeal carcinoma or recurrent nasopharyngeal carcinoma, were not significantly different from healthy controls ( Table 2 ; Fig. 2 ). In contrast, the plasma osteopontin levels in nasopharyngeal carcinoma patients with distant metastases were significantly higher (even after Bonferroni correction) than that of healthy controls (P < 0.001 for the comparison of means by Student's t test, and P < 0.005 for the comparison of difference by Mann-Whitney U test; Table 2 ).
Plasma osteopontin and response to radiotherapy in nasopharyngeal cancer. There were 32 patients in group (a) with newly diagnosed locoregional and nonmetastatic nasopharyngeal carcinoma. All received curative radiotherapy with or without concurrent chemotherapy, except one patient who refused radiotherapy (this patient was excluded from the following analysis). Patients with stage I to II disease were treated with radiotherapy alone (n = 10), and patients with stage III to IVB disease were given weekly cisplatin concurrent with radiotherapy (concurrent chemoradiation, n = 21), according to departmental clinical protocol (37) . The response in primary tumor was evaluated by nasopharyngoscopy and biopsy at 6 weeks after completion of radiotherapy. Nodal response was evaluated by clinical examination at end of radiotherapy. Response was classified according to WHO response criteria (38) . At the end of planned radiotherapy, 20 patients achieved complete response, 10 patients had partial response, and 1 had progressive disease. Of the 10 patients with residual tumor at Fig. 1 . A, osteopontin secretion by nasopharyngeal carcinoma cells after exposure to hypoxia condition. CNE-2 cells were incubated in normal (solid line) or hypoxia (dotted line) condition for 4 to 48 h. At the end of incubation, cultured medium was collected and osteopontin secretion to cultured medium was quantified by an osteopontin ELISA kit. Cells in each well were collected and the cellular proteins were quantified. Osteopontin secretion was then normalized by total protein in each well. B, cellular osteopontin levels in nasopharyngeal carcinoma cells after exposure to hypoxia condition. Nasopharyngeal carcinoma cells were subjected to hypoxia treatment for 4 to 48 h. At the end of incubation, cells were collected and lysed. Total cell lysates were analyzed by SDS-PAGE followed by immunoblotting with anti-HIF-1a, antiosteopontin, or antiactin antibodies. Actin was used as an internal control to verify equal protein loading. C, expression of osteopontin mRNA in nasopharyngeal carcinoma cells after exposure to hypoxia condition. Nasopharyngeal carcinoma cells were incubated in normal (-) or hypoxia (H) conditions for 16 h. At the end of incubation, cells were collected and total RNA was extracted. Reverse transcription-PCR was then done.The PCR-amplified cDNA derived from osteopontin and glyceraldehyde 3-phosphate dehydrogenase were separated by 1.8% agarose gel electrophoresis containing ethidium bromide. D, cellular osteopontin levels in nasopharyngeal carcinoma cells after exposure to hypoxia/reoxygenation condition. Nasopharyngeal carcinoma cells were subjected to hypoxia (H) treatment for 16 h followed by 2 to 48 h of reoxygenation (R). At the end of incubation, cells were collected and lysed. Total cell lysates were analyzed by SDS-PAGE followed by immunoblotting with antiosteopontin antibody.
end of radiotherapy, 9 were successfully salvaged by additional radiotherapy delivered to the residual tumor bed (6 in the neck, and 3 in the nasopharynx including 1 followed by nasopharyngectomy). After a median follow-up of 2 years for this cohort (n = 31), 7 patients relapsed and 3 patients died (all from nasopharyngeal carcinoma recurrence). The response to planned radiotherapy (complete response versus partial response/progressive disease) was found to be a significant predictor of relapse (P = 0.036; odds ratio, 7.5; 95% confidence interval, 1.14-49.3).
When plasma osteopontin were dichotomized into high (>median 545 ng/mL) and low level (Vmedian), nasopharyngeal carcinoma patients with high plasma osteopontin at diagnosis were found to be significantly less likely to achieve complete response after radiotherapy compared with those with low plasma osteopontin. The complete response rate was 40% (6 of 15) versus 88% (14 of 16) for high versus low plasma osteopontin, respectively (P = 0.009, Fisher's exact test). When plasma osteopontin was analyzed as a continuous variable, plasma osteopontin remained a significant predictor for tumor response after radiotherapy (P = 0.010, logistic regression). For nasopharyngeal carcinoma patients treated with concurrent chemoradiation (n = 21), plasma osteopontin was also a significant predictor of response to concurrent chemoradiation. The complete response rate was 20% (2 of 10) versus 82% (9 of 11) for high versus low plasma osteopontin, respectively (P = 0.009, Fisher's exact test). When plasma osteopontin was analyzed as a continuous variable, plasma osteopontin remained Research.
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The ability of plasma osteopontin and other clinical characteristics to predict the response to radiotherapy was further tested in both univariate and multivariate logistic regression models. On univariate analysis, T stage, N stage, International Union Against Cancer overall stage, and plasma osteopontin were significant predictors of complete response to radiotherapy (Table 3A) . When we incorporated these significant predictors from univariate analysis into a multivariate model, plasma osteopontin remained a significant and independent predictor of response to radiotherapy (Table 3B) .
Discussion
Osteopontin has recently received attention as a secreted biomarker of tumor hypoxia. In their original report identifying osteopontin as a potential hypoxia marker, Le et al. showed that the expression of the osteopontin gene was inversely related with the expression of the von-Hippel-Lindau (VHL) gene that has a central role in the degradation of the transcription factor subunit HIF-1a and is therefore linked to the hypoxic response of cells (11) . Their data suggested that cells with low VHL expression had intermediate to high osteopontin protein levels, and cells with high VHL expression had low osteopontin protein levels. Le et al. also investigated the level of intracellular and secreted osteopontin proteins in one head and neck squamous cell carcinoma cell line, SCC4, after exposure to either normoxia or a different time course of hypoxia (<0.05% oxygen). Based on the experiment from a single cell line, the authors suggested that hypoxia and reoxygenation stimulated osteopontin extracellular secretion (11) .
We studied the effect of hypoxia on osteopontin secretion and expression in a panel of four well-characterized nasopharyngeal carcinoma cell lines (8, 32) . Of the four nasopharyngeal carcinoma cell lines used, three of them were established from poorly differentiated or undifferentiated nasopharyngeal carcinoma. C666-1 also carried EBV in long-term cultures. In Southern China, most of nasopharyngeal carcinomas are considered as undifferentiated carcinomas of the nasopharyngeal type (95%) and are strongly associated with EBV (39). Our results showed that osteopontin was expressed by all four nasopharyngeal carcinoma cell lines under normoxia but was only secreted by CNE2. However, hypoxia had no significant effect on either the intracellular mRNA and protein expression or the extracellular secretion of osteopontin in nasopharyngeal carcinoma cell lines. Reoxygenation also had no effect on intracellular osteopontin protein expression. To validate the hypoxic condition created by the hypoxia chamber, we also examined the expression of the levels of the HIF-1a protein, which is induced by hypoxia, in the nasopharyngeal carcinoma cell lines. The Western blotting results showed that the HIF-1a protein was elevated in all four nasopharyngeal carcinoma cell lines after hypoxia treatment. In addition, we also observed that a moderate induction of HIF-1a protein level in some of the nasopharyngeal carcinoma cell lines during incubation in normoxia condition. This moderate elevation may be due to the stress/starvation created by incubating cells in medium with only 1% FBS, as this was not seen when cells were incubated in 5% or 10% FBS in our previous report (8) . This difference between the nasopharyngeal carcinoma cell lines and the SCC4 cell line could be explained by the genetic background of the cell lines investigated. Whereas the VHL gene was not mutated (40) or methylated (41) in nasopharyngeal carcinoma, the VHL status of the other cell lines has not been published. Recent in vivo and in vitro studies by other investigators also supported that hypoxia-induced osteopontin up-regulation is not consistent and may be cell type -specific (42, 43) . Said et al. studied osteopontin secretion from cultured cell lines. Of six cell lines tested, only three, A549 (human lung carcinoma), HT1080 (human fibrosarcoma), and U87 (human malignant glioma), showed detectable osteopontin under aerobic condition. No increase of osteopontin in the medium during 24 hours hypoxia but moderate increases during subsequent reoxygenation were observed in these three cell lines. In FaDu (human pharyngeal carcinoma), HT 29, and HCT 116 (human colorectal carcinoma cells), osteopontin levels were undetectable under all conditions (42). Sorensen et al. also showed that osteopontin was up-regulated by hypoxia in SiHa (human uterine cervix squamous cell carcinoma) cells but not in FaDu DD (pharyngeal squamous cell carcinoma, a subline of FaDu) cells (44) .
Another possible explanation for the discrepancy between high plasma osteopontin levels in patients with hypoxic tumors and a lack of protein secretion during hypoxia in tumor cell cultures may be the contribution of nontumor cells. At present, the exact source(s) of the elevated osteopontin in the sera or plasma of cancer patients remains unclear. Osteopontin is a secreted phosphoprotein that can be expressed at high level by T-lymphocytes, epidermal cells, bone cells, macrophages, endothelial cells, and tumor cells in remodeling processes such as inflammation, ischemia-reperfusion, bone resorption, arteriosclerosis, and tumor progression (45) . Although osteopontin may be expressed in tumor cells, osteopontin in blood may be derived from several possible tissue sources, including activated secretary epithelia, remodeling of bone or vascular bed, activated immune cells, and/or tumor cells. In pancreatic adenocarcinoma, activated tumor-infiltrating macrophages have been suggested as a primary source of osteopontin (18) . In a recent study of advanced head and neck cancer patients, no correlation was found between plasma osteopontin and tumor osteopontin expression (13) . Despite the uncertainty on the possible source(s) and mechanism(s) of elevated plasma osteopontin in health and disease states, plasma osteopontin has been extensively investigated as a biomarker of advanced disease in multiple tumor types (15 -30) , and has been implicated as an important mediator in tumor metastasis, as summarized in a recent review (45) . Our results showed that plasma osteopontin was not elevated in localized nasopharyngeal carcinoma (either newly diagnosed or recurrent) but was increased in metastatic nasopharyngeal carcinoma. This supports for a role of osteopontin in tumor metastasis.
We also showed that high plasma osteopontin was a significant negative predictor of response to radiotherapy in nasopharyngeal carcinoma. This suggests that high plasma osteopontin may be a biomarker of radiation resistance. In nasopharyngeal carcinoma patients treated with concurrent chemoradiation, the fact that plasma osteopontin remains a significant negative predictor of radiotherapy response suggests that an alternative strategy other than addition of chemotherapy should be explored in the future to overcome the poor response to radiotherapy associated with a high plasma osteopontin level. However, because of the small sample size and the lack of long term follow-up, we could not address the effect on relapse and survival in this pilot study. Our observations and hypothesis should therefore be confirmed in a larger clinical study in nasopharyngeal carcinoma.
Our clinical data indicated that in patients with locoregional nasopharyngeal carcinoma, plasma osteopontin was not different from that in healthy controls but nevertheless was predictive of radiotherapy response. Taken together with the in vitro data of the lack of hypoxia induction of osteopontin in nasopharyngeal carcinoma cell lines, our findings challenged the view that osteopontin secretion is directly caused by the effect of low oxygen tension on tumor cells. It was still possible, however, that plasma osteopontin was related to intratumoral hypoxia and prognostic, but was not secreted directly from the tumor cells. Defining the exact mechanism of elevated plasma osteopontin levels in cancer and the relationship to tumor hypoxia will require further investigations.
Recently, Vordermark et al. showed that the commercially available osteopontin ELISA systems produce different absolute plasma osteopontin levels, compromising any direct comparison of individual patient data with published results (46) . It seemed that the discrepancy may be related to a difference in the epitope recognition site of the different capture antibodies provided with individual ELISA kits. In addition, the type of blood sample used (e.g., plasma versus serum) and variations in sample processing and storage may also affect the results of ELISA. To further complicate the measurement of plasma osteopontin, it is known that osteopontin exist in various forms due to posttranslational modifications such as glycosylation, sulfation, and phosphorylation. There are at least three differentially spliced isoforms of human osteopontin. The use of various combinations of antibodies raised against four different portions of human osteopontin in a total of six separate ELISA systems has been shown to recognize distinct truncated or glycosylated forms of osteopontin (47) . However, the potential functional differences among those isoforms are largely unknown, and the differential expression of osteopontin fragments in various disease states is not well characterized. Therefore, a prospective validation study for each specific tumor type is required before plasma osteopontin can be widely used in the clinic to guide clinical decision.
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